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Summary
Background.  —  Digoxin  is  highly  potent  and  efﬁcacious  for  treatment  of  heart  failure  (HF)  and/or
atrial ﬁbrillation  (AF)  yet  compliance  is  often  poor.
Aims. —  To  examine  prevalence  rates  of  non-compliance  with  digoxin;  variations  between
clinical settings,  types  of  non-compliance  and  methods  of  detection;  and  potential  factors
inﬂuencing  non-compliance  with  digoxin.
Methods.  —  This  was  a  systematic  review  and  meta-analysis  of  prospective  observational  stud-
ies of  non-compliance  with  digoxin  in  patients  with  HF  and/or  AF,  published  in  English.  The
studies were  identiﬁed  through  these  bibliographic  databases:  MEDLINE,  EMBASE,  CINAHL,  IPA
and Cochrane  CENTRAL.  Subgroup  analysis  examined  the  inﬂuence  of  clinical  settings,  types  of
non-compliance  and  methods  of  detection.
Results.  —  Ten  studies  met  the  inclusion  criteria,  comprising  1841  patients  with  HF  and/or  AF.ce  rates  of  non-compliance  for  outpatients,  after  hospital  dischargeThe corresponding  prevalen
and inpatients  were  43.1%  (interquartile  range  [IQR]  29—48%),  25%  (95%  conﬁdence  interval  [CI]
12—37%) and  4.5%,  respectively.  In  patients  with  HF  and  AF  co-morbidities,  the  prevalence  rate
of non-compliance  with  digoxin  was  38.7%  (IQR  27—46%);  the  corresponding  prevalence  rates  of
overdosing and  underdosing  were  33.04%  (IQR  22—49%)  and  33.8%  (95%  CI  25—42%),  respectively.
Abbreviations: AF, atrial ﬁbrillation; CHF, congestive heart failure; CI, conﬁdence interval; df, degrees of freedom; HF, heart failure;
IQR, interquartile range; SDC, serum digoxin concentration.
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Rates  varied  depending  on  the  methods  of  detecting  non-compliance.  Regularity  of  prescribed
dose, diuretic  use,  coronary  artery  bypass,  implantable  cardioverter-deﬁbrillator,  number  of
ofﬁce visits  and  pill  boxes  demonstrated  strong  associations  with  non-compliance  with  digoxin.
Conclusions.  —  Non-compliance  with  digoxin  is  prevalent  among  patients  with  HF  and/or  AF.  A
better understanding  of  the  factors  inﬂuencing  compliance  and  improved  intervention  strategies
are necessary  to  increase  digoxin  compliance.
© 2012  Published  by  Elsevier  Masson  SAS.
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Résumé
Contexte.  —  La  digoxine  est  très  puissante  et  efﬁcace  contre  l’insufﬁsance  cardiaque  (IC)  et/ou
la ﬁbrillation  auriculaire  (FA),  cependant  l’observance  du  traitement  est  souvent  médiocre.
Objectifs.  —  Examiner  la  prévalence  de  la  non-observance  au  traitement  par  digoxine  et  ses
variations  en  fonction  des  données  cliniques,  des  types  de  non-observance  et  de  leur  mode  de
détection ;  en  identiﬁer  d’éventuels  facteurs  prédictifs.
Méthodes.  —  Synthèse  et  méta-analyse  de  dix  études  observationnelles  prospectives.  Patients
atteints  d’IC  et/ou  de  FA  traités  par  digoxine.  Nous  avons  identiﬁé  par  un  examen  systématique
des bases  de  données  bibliographiques  (MEDLINE,  EMBASE,  CINAHL,  IPA  et  à  Cochrane  CEN-
TRAL), les  études  prospectives,  publiées  en  anglais,  sur  la  non-observance  à  la  digoxine  chez
les patients  présentant  une  IC  et/ou  une  FA.  Nous  avons  réalisé  des  analyses  de  sous-groupes
pour examiner  l’inﬂuence  des  conditions  de  traitement,  des  types  de  non-observance  et  de
méthodes  de  détection  sur  la  non-observance.
Résultats.  —  L’analyse  statistique  a  été  réalisée  avec  STATA  v10.  Dix  études  regroupant  un  total
de 1841  patients  répondaient  aux  critères  d’inclusion.  La  prévalence  de  la  non-observance  chez
les patients  ambulatoires,  après  hospitalisation,  et  en  cours  d’hospitalisation  est  respective-
ment de  43,07  %  (Intervalle  InterQuantile  [IIQ]  29,02—48,24  %)  ;  25,10  %  (IC  95  %  12,20—37,90  %)  ;
et 4,51  %.  Dans  le  groupe  des  patients  ayant  une  complication  liée  à  l’IC  ou  à  la  FA,  la
prévalence  de  la  non-observance  à  la  digoxine  est  de  38,74  %  (IIQ  27,59—46,93  %)  ;  et  les  pré-
valences  correspondant  à  celles  des  sur-  et  des  sous-dosages  sont  respectivement  de  33,04  %
(IIQ 22,15—49,42  %)  et  33,8  %  (95  %  CI  25,40—42,20  %).  Ces  taux  varient  en  fonction  des  types
de non-observance  et  de  leurs  méthodes  de  détection.  L’utilisation  de  doses  stables  de  digo-
xine, la  coprescription  de  diurétiques,  les  antécédents  de  pontage  coronaire,  d’implantation  de
déﬁbrillateur,  la  fréquence  du  suivi  médical  et  l’utilisation  d’un  pilulier  sont  fortement  corrélés
à la  non-compliance.
Conclusions.  — La  prévalence  de  la  non-compliance  au  traitement  par  digoxine  des  patients
en IC  et/ou  FA  est  importante.  Une  meilleure  compréhension  des  facteurs  qui  l’inﬂuencent
et le  développement  de  stratégies  d’intervention  efﬁcaces  sont  nécessaires  pour  améliorer
l’observance  des  prescriptions  de  digoxine.
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on-compliance  with  medication  regimens  is  considered  as
ne  of  the  major  problems  in  patients  with  heart  failure
HF)  and/or  atrial  ﬁbrillation  (AF);  it  can  lead  to  intox-
cation  or  missed  therapeutic  effects  [1—3]. Digoxin  is
he  cardiac  glycoside  most  commonly  used  to  treat  these
atients  and  has  many  positive  factors:  reduced  morbid-
ty,  reduction  of  mortality  at  low  dose  and  low  cost  with  a
avourable  cost-effectiveness  ratio  [4—6]. Currently,  digoxin
s  recommended  for  the  treatment  of  the  following  con-
itions:  HF  in  sinus  rhythm  with  reduced  left  ventricular
jection  fraction  and  symptoms  of  HF,  despite  the  use
f  diuretics,  beta-blockers,  angiotensin-converting  enzyme
nhibitors/angiotensin  receptor  blockers  or  aldosterone
eceptor  antagonists  [7,8]; AF  with  HF  or  left  ventricular
ysfunction  [9].  Although  information  on  compliance  with
his  drug  is  regarded  as  one  of  the  important  factors  for
he  effective  use  of  digoxin  in  these  groups  of  patients  [10],
d
d
(n  SAS.
uch information  is  rare.  Previous  systematic  reviews  have
xamined  non-compliance  with  medications  in  HF  patients,
ut  limited  attention  has  been  given  to  the  issues  of  study
esign,  clinical  settings,  types  of  non-compliance  and  meth-
ds  for  detecting  non-compliance  [3,11,12].  This  systematic
eview  and  meta-analysis  addresses  these  questions  by  dis-
ussing  the  prevalence  rates  of  non-compliance  with  digoxin
n  patients  with  HF  and/or  AF  and  describes  potential  factors
nﬂuencing  non-compliance  with  digoxin.
ethods
ata source and study selection
he  inclusion  criteria  for  our  review  were  as  follows:ata  to  calculate  the  prevalence  of  non-compliance  with
igoxin;  studies  conducted  in  patients  with  congestive  HF
CHF)  and/or  AF;  studies  published  in  English.
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Outcome measures
This  review  focused  on  prevalence  rates  of  non-compliance
with  digoxin  as  the  primary  outcome  measure  and  the  effect
size  of  the  associations  between  potential  factors  and  non-
compliance  with  digoxin  as  the  secondary  outcome  measure.
Search strategy
The  following  bibliographic  databases  were  systematically
searched  from  their  inception  date  to  June  2012:  MEDLINE,
Excerpta  Medica  Database  (EMBASE),  Cumulative  Index  to
Nursing  and  Allied  Health  Literature  (CINAHL),  International
Pharmaceutical  Abstracts  (IPA)  and  Cochrane  CENTRAL.  The
key  words  ‘digoxin’;  ‘(non)  compliance’;  ‘(non)  adherence’;
‘(congestive)  heart  failure’  and  ‘atrial  ﬁbrillation’  were  used
in  combination  with  MeSH  terms  and  EMTREE.  The  literature
retrieval  was  supplemented  by  hand  searching  the  reference
lists  of  all  identiﬁed  articles.
Data extraction and manipulation
Data  were  extracted  on  study  design  and  prevalence  rate  of
non-compliance  with  digoxin  was  recorded  on  a  data  extrac-
tion  form.  Other  information  included  methods  for  detecting
non-compliance,  study  population,  study  setting,  the  use  of
digoxin  (i.e.  digoxin  dose)  and  the  effect  size  of  the  asso-
ciations  between  inﬂuencing  factors  and  non-compliance
with  digoxin.  One  study  provided  the  effect  size  from  both
univariate  and  multivariate  analyses  [13]. The  direct  associ-
ation  between  a  potential  factor  and  non-compliance  from
univariate  analysis  rather  than  multivariate  analysis  was
used  to  determine  the  effect  size  of  the  association  between
an  inﬂuencing  factor  and  non-compliance  with  digoxin.  One
study  reported  prevalence  rates  at  different  points  of  time
after  discharge;  we  used  the  prevalence  rate  detected  at  the
time  closest  to  those  in  other  included  studies  [14]. In  addi-
tion,  one  study  reported  outcome  of  non-compliance  as  a
percentage  of  compliance  but  did  not  deﬁne  the  benchmark
for  classiﬁcation  as  compliant  [15]; patients  who  recorded
a  compliance  percentage  greater  or  equal  to  80%  were  cat-
egorized  as  compliant  [16]. Cochrane’s  risk  of  bias  and  the
component  approach  were  adopted  for  assessing  study  qual-
ity  [17,18].
Data analysis
Prevalence  rates  of  non-compliance  with  digoxin  were  cal-
culated  for  each  study;  these  were  derived  by  dividing  the
number  of  patients  who  were  non-compliant  by  the  total
number  of  patients  using  digoxin.  The  effect  size  (r)  was
calculated  from  exact  P  values  when  r  was  not  reported  in
the  original  studies  [19,20].  The  effect  size,  in  behavioural
science  research,  can  be  considered  small  when  r ≤  0.10,
medium  when  r  =  0.25  and  large  when  r  ≥  0.40  [21].
A  statistical  test  of  heterogeneity  was  performed
using  the  Cochran-Mantel-Haenszel  method.  The  degree  of
between-study  heterogeneity  was  assessed  using  2 and
I2 tests  to  determine  whether  it  would  be  appropriate  to
compute  a  meta-analytical  summary  estimate  [22]. The
summary  weighted  mean  differences  and  95%  conﬁdence
intervals  (CI)  were  calculated  based  on  a  random-effects
t
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cation  509
odel  using  the  DerSimonian-Laird  method  [23]. Conﬁdence
ntervals  for  I2 were  also  obtained  to  convey  uncertainty
n  I2 [24]. The  results  across  these  studies  were  summa-
ized  using  the  median  and  interquartile  range  (IQR)  if
here  was  signiﬁcant  heterogeneity  between  studies.  The
ncluded  studies  were  divided  into  subgroups  to  explore
ossible  reasons  for  heterogeneity:  the  settings  in  which
on-compliance  had  occurred  (outpatient,  after  hospi-
al  discharge,  or  inpatient);  the  types  of  non-compliance
overdose  or  underdose);  the  methods  for  detecting  non-
ompliance  (pill  count,  interview,  measurement  of  serum
igoxin  concentration  [SDC]  or  combination  method  [inter-
iew  conﬁrmed  by  SDC]).  If  one  study  reported  more  than
ne  method  for  detecting  non-compliance  for  each  type  of
on-compliance,  we  used  data  from  objective  measures  (i.e.
DC  measurement  or  combination  method)  for  the  analysis.
TATA  statistical  software  was  used  to  perform  all  statisti-
al  analyses  (version  10.0;  StataCorp,  College  Station,  TX,
SA).
esults
tudy and patient characteristics
en  studies  met  the  inclusion  criteria,  comprising  a  total
f  1841  patients  with  CHF  and/or  AF  (Fig.  1)  and  covering
he  period  1973—2010.  Eight  studies  reported  preva-
ence  rates  of  non-compliance  with  digoxin  in  outpatients
13,14,25—30],  three  studies  reported  prevalence  rates
fter  hospital  discharge  [13,15,31]  and  one  study  reported
revalence  rates  in  inpatients  [13]. A  summary  of  the  study
haracteristics  is  presented  in  Table  1.  The  studies  were
ndertaken  in  North  America  [29], Europe  [14,15,27,28,31],
sia  [13,25,26]  and  Africa  [30]. Six  studies  were  under-
aken  before  the  era  of  angiotensin-converting  enzyme
nhibitors/angiotensin  receptor  blockers  and  beta-blockers
14,15,28—31]. All  studies  were  conducted  in  older  adults  or
he  elderly.  Four  studies  were  conducted  in  patients  with  co-
orbidities  of  CHF  with  AF,  including  a  total  of  877  patients
13,15,29,31].  The  mean  daily  digoxin  maintenance  dose,
he  number  of  daily  digoxin  tablets  and  the  total  number  of
ablets  of  all  medications  reported  in  the  included  studies
re  also  shown  in  Table  1.
on-compliance with digoxin in outpatients
ight  studies  examined  the  prevalence  of  non-compliance
ith  digoxin  in  outpatients  (n  =  1262);  491  patients  were
ssociated  with  non-compliance  [13,14,25—30]. High  het-
rogeneity  was  observed  in  the  studies  in  outpatients  (2
3.40  [degrees  of  freedom  (df)  7],  P  <  0.001;  I2 91.60%,
5%  CI  85.85—95.02).  The  median  prevalence  rate  of  non-
ompliance  with  digoxin  in  outpatients  was  43.07%  (IQR
9.02—48.24%).  Six  studies  [13,14,25,26,28,29]  reported
revalence  rates  of  overdosing  and  ﬁve  reported  preva-
ence  rates  of  underdosing  [14,26,27,29,30].  The  results
f  heterogeneity  testing  were  high  in  outpatients  for  both
he  overdose  subgroup  (2 358  [df  5],  P  <  0.001;  I2 98.60%,
5%  CI  98.01—99.02)  and  the  underdose  subgroup  (2 19.96
df  4],  P  =  0.001;  I2 80.00%,  95%  CI  52.74—91.50).  The
orresponding  median  prevalence  rates  of  overdosing  and
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Table  1  Characteristics  of  the  included  studies.
Study  (year)  [Ref.] Country  Study  population  Types  of  non-compliance  Method  of  detecting
non-compliance
Weintraub  (1973)  [29]  USA  Outpatients  with  CHF  and/or  arrhythmia  Underdosing/overdosing  Interview;  interview  +  SDC
Johnston  (1978)  [14]  Ireland  Outpatients  Underdosing/overdosing  SDC;  pill  count
Johnston
(1978)
[31]
Ireland Patients
discharged  from
hospitalb
Underdosing/  SDC
Overdosing SDC;  pill  count
Interview  +  SDC
Taggart  (1981)  [28]  Ireland  Outpatient  Overdosing  SDC;  pill  count
Wiseman  (1991)  [30]  South  Africa  Outpatients  with  HF  Underdosing  Interview  +  SDC
Kruse  (1992)  [15]  Germany  Elderly  patients  with  HF  and/or  AF
discharged  from  hospital
Underdosing  Pill  counti
Miura  (2000)  [13] Japan Outpatients  with  CHF  and/or  AF  Overdosing  SDC
Patients  discharged  from  hospital  Overdosing  SDC
Inpatients  with  CHF  and/or  AF  Overdosing  SDC
Miura  (2001)  [25] Japan Outpatients  with  CHF  and  supraventricular
tachycardia
Overdosing  SDC
Modares-Mosadegh
(2001)  [26]
Iran Outpatients  with  CHF  Underdosing/overdosing  SDC
Muzzarelli  (2010)  [27]  Switzerland  Symptomatic  CHF  (NYHA  >  class  II)  Underdosing  Interview;  SDC;
interview  +  SDC
Study  (year)
[Ref.]
No.  of  participants
(No.  of  men)
Mean  digoxin
dose  (SD)  (mg/d)
Mean  No.  of  daily
digoxin  tablets  (SD)
Mean  No.  of  daily
tablets  (SD)
C  NC  C  NC  C  NC  C  NC
Weintraub
(1973)  [29]
75 (NA)  37  (NA)  0.25  (NA)  0.24  (NA)  NA  NA  NA  NA
Johnston
(1978)  [14]
27 (12)  23  (7)  0.22  (0.12)  0.22  (0.12)  1.3  (0.5)  1.5  (0.7)  4.3a (3.3)  5.3a (3.5)
N
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Table  1  (Continued  )
Study  (year)
[Ref.]
No.  of  participants
(No.  of  men)
Mean  digoxin
dose  (SD)  (mg/d)
Mean  No.  of  daily
digoxin  tablets  (SD)
Mean  No.  of  daily
tablets  (SD)
C NC C NC C NC C NC
Johnston  (1978)
[31]
25c (14)  18c,g (5)  NA  NA  1.26  (0.55)  1.22  (0.56)  6.6  (3.7)  6.6  (3.9)
22d (NA)  8d (NA)  NA NA NA NA NA NA
14e (NA)  6e (NA)  NA NA NA NA NA NA
Taggart  (1981)
[28]
25 (NA) 23  (NA) 0.25  (NA) 0.25  (NA) 1,2,4h (NA)  1,2,4h (NA)  NA NA
Wiseman
(1991)  [30]
82 (NA) 55  (NA) NA NA NA NA NA NA
Kruse  (1992)
[15]
5j (2)  4j (2)  0.25  (NA) 0.25  (NA) 1  (NA) 1  (NA) NA NA
Miura  (2000)  [13] 253  (NA) 72  (NA) 0.21  (0.08) 0.24  (0.09) NA NA NA NA
45f (NA)  10f (NA)  NA NA NA NA NA NA
496  (NA) 22  (NA) NA NA NA NA NA NA
Miura  (2001)
[25]
218  (17)  213  (16)  NA  NA  NA  NA  NA  NA
Modares-
Mosadegh
(2001)  [26]
63 (32) 56  (27) 0.19  (NA) 0.21  (NA) 0.5  or  1
tablets/day  or
5  or  6
tablets/week
0.5 or  1
tablets/day  or
5  or  6
tablets/week
3.64 (1.14) 3.78  (1.36)
Muzzarelli
(2010)  [27]
30k (24)  10k (9)  NA NA NA NA 13  (5)  8  (4)
AF: atrial ﬁbrillation; C: compliance; CHF: chronic heart failure; LVEF: left ventricular ejection fraction; NA: not applicable; NC: non-compliance; NYHA: New York Heart Association; SD:
standard deviation; SDC: serum digoxin concentration.
a Number of other tablets except digoxin.
b Each participant’s digoxin concentrations were assessed from day 8 to either 4 weeks or 3 months after discharge from hospital.
c At day 8.
d At 4 weeks.
e At 3 months.
f At 6 months after discharge from hospital.
g Seven patients were excluded because of a signiﬁcant deterioration in renal function.
h Each participant received one, two or four tablets daily; this was determined randomly using a Latin square design.
i Medication Event Monitoring System (MEMS).
j The percentage of prescribed dose taken was used to evaluate digoxin compliance but the study did not determine the deﬁnition of non-compliance; the author deﬁned non-compliance
as less than 80% of the prescribed dose taken.
k Patients remaining after 6 months (n = 31; one patient died, six patients withdrew consent and two patients stopped digoxin because of adverse effects).
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pigure 1. Study ﬂow. AF: atrial ﬁbrillation; CHF: congestive hear
nderdosing  were  23.08%  (IQR  9.24—49.42%)  and  25.00%  (IQR
0.00—29.41%),  respectively.
Among  six  studies  that  reported  overdosing  of  digoxin,
ve  studies  [13,14,25,26,28]  used  SDC  measurement  for
etecting  non-compliance,  one  study  [28]  used  pill  count
nd  another  used  the  combination  of  interview  con-
rmed  by  SDC  [29]. High  heterogeneity  was  found  within
he  studies  using  the  SDC  method  (2 151.96  [df  4],
 <  0.001;  I2 97.40%,  95%  CI  95.74—98.37)  in  the  overdosing
roup  of  outpatients.  The  median  prevalence  rate  of  non-
ompliance  across  the  SDC  measurement  was  22.15%  (IQR
6.00—49.42%).
g
C
gure.
The  effect  of  detection  method  on  the  prevalence  rates
f  non-compliance  in  the  underdosing  group  of  outpatients
as  investigated:  one  study  used  pill  counts  [14], three
sed  SDC  [26,27,29], two  using  interview  [27,29]  and  three
sed  interview  conﬁrmed  by  SDC  [27,29,30]. Heterogene-
ty  within  the  subgroup  that  used  the  SDC  method  (2
.36  [df  2],  P  =  0.186;  I2 40.50%,  95%  CI  0—81.75)  was
nsigniﬁcant  with  moderate  inconsistency  [26,27,29]. The
revalence  rate  of  non-compliance  for  the  underdosing
roup  of  outpatients  detected  by  the  SDC  was  23.30%  (95%
I  16.60—30.10%),  as  illustrated  in  Fig.  2.  However,  hetero-
eneity  was  identiﬁed  in  the  interview  method  subgroup  (2
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(I2 = 40.5%, P = 0.19).
6.30  [df  1],  P  =  0.012;  I2 84.10%,  95%  CI  34.66—96.14)  and  the
combination  method  subgroup  (interview  conﬁrmed  by  SDC)
(2 11.07  [df  2],  P  =  0.004;  I2 81.90%,  95%  CI  44.18—94.15).
Higher  prevalence  rates  were  found  in  studies  that  used  the
combination  method  (interview  conﬁrmed  by  SDC)  (25.00%,
IQR  12.50—32.85%)  than  in  those  that  used  SDC  alone,  the
interview  method  (24.02%,  IQR  15.00—33.04%)  or  pill  count
(crude  prevalence  rate  20%,  n  =  10/50).
Four  out  of  the  eight  studies  in  outpatients  speciﬁcally
examined  prevalence  of  non-compliance  with  digoxin  in
patients  with  co-morbidities  with  HF  and  AF  (n  =  877);  326
patients  were  non-compliant.  Heterogeneity  within  these
studies  was  high  (2 67.47  [df  3],  P  <  0.0001;  I2 95.60%,  95%
CI  91.48—97.68).  The  median  prevalence  rate  in  this  group
of  patients  was  38.74%  (IQR  27.59—46.93%)  [13,15,25,29].
Three  studies  [13,25,29]  reported  prevalence  rates  of  over-
dosing  and  two  studies  [15,29]  reported  prevalence  rates
of  underdosing.  The  overdosing  subgroup  (2 67.14  [df  2],
P  <  0.0001;  I2 97.00%,  95%  CI  94.01—98.52)  was  heteroge-
neous,  while  the  underdosing  subgroup  (2 0.44  [df  1],
P  =  0.506;  I2 0.00%,  95%  CI  not  applicable)  was  homoge-
neous.  The  median  prevalence  rate  of  digoxin  overdosing
was  33.04%  (IQR  22.15—49.42%)  and  of  digoxin  underdosing
was  33.8%  (95%  CI  25.40—42.20%).
Non-compliance with digoxin after hospital
discharge
Three  studies  reported  prevalence  of  non-compliance  with
digoxin  after  hospital  discharge  (n  =  84);  20  patients  showed
non-compliance  [13,15,27]. Based  on  the  heterogeneity
test,  these  studies  were  homogeneous  (2 2.98  [df  2],
P  =  0.225;  I2 32.90%,  95%  CI  0—97.75).  The  pooled  mean
prevalence  rate  of  non-compliance  was  25.10%  (95%  CI
12.20—37.90%).Non-compliance with digoxin for inpatients
Only  one  study  examined  inpatient  non-compliance  with
digoxin  (n  =  518);  22  patients  were  associated  with
n
m
r
tp of outpatients, detected by serum digoxin concentration. Overall
on-compliance  [13], representing  a  non-compliance  rate
f  4.51%.
otential factors inﬂuencing non-compliance
ith digoxin
ive  studies  reported  on  potential  factors  inﬂuencing
ompliance  with  digoxin  [13,15,25,27,29].  Twenty-four  fac-
ors  were  identiﬁed,  as  shown  in  Table  2.  A  heterogeneity
est  was  performed  in  eight  potential  factors  for  non-
ompliance  with  digoxin,  including:  duration  of  therapy;
nderstanding  the  medication;  understanding  the  illness;
otal  number  of  drugs  prescribed;  diuretic  use;  regularity  of
rescribed  dose;  patient  age;  and  sex.  No  heterogeneity  was
dentiﬁed  within  the  following  factors:  understanding  the
edication;  understanding  the  illness.  Age,  sex,  regularity
f  prescribed  dose,  number  of  drugs  and  diuretic  use  were  all
eterogeneous  (Table  2).  The  inﬂuence  was  considered  to  be
trong  for  six  factors  (regularity  of  prescribed  dose,  diuretic
se,  coronary  artery  bypass  graft,  implantable  cardioverter-
eﬁbrillator,  number  of  consultation  visits  and  pill  box),
mong  which  diuretic  use  was  the  strongest.  Understanding
he  medication,  number  of  co-morbidities,  prior  hospitaliza-
ion  for  CHF  and  marital  status  showed  medium  effect  size.
he  effect  size  for  the  other  14  factors  was  deemed  to  be
mall.
iscussion
his  systematic  review  and  meta-analysis  suggests  that  non-
ompliance  is  a  signiﬁcant  persisting  burden  that  limits  the
ffective  use  of  digoxin  in  patients  with  HF  and/or  AF;  nearly
alf  of  the  outpatients  treated  with  digoxin  and  one-fourth
f  patients  after  hospital  discharge  were  non-compliant
ith  therapy.  In  particular,  two-ﬁfths  of  the  outpatients
ith  co-morbidities  for  which  digoxin  was  required,  were
on-compliant.  In  light  of  the  complexity  in  current  phar-
acotherapy  for  patients  with  HF  and/or  AF,  the  present
eview  also  implies  that  this  group  was  non-compliant  with
heir  other  medications  [12]. Multidisciplinary  interventions
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Table  2  Potential  factors  affecting  non-compliance  with  digoxin.
Inﬂuencing  factors  No.  of  studies  [Refs.]  Crude  effect  size  Heterogeneity
test
Overall  effect
size
Duration  of  therapy 2  [13,26]  (+)  0.032  2 0.07  (df  1),
P  =  0.789;
I2 0.00%  [95%  CI
NA]
(+) 0.034
[0.017—0.050]a
Understanding  the  medication 2  [13,27] (+) 0.29 2 0.79  (df  1),
P  =  0.374;
I2 0.00%  [95%  CI
NA]
(+) 0.034
[0.017—0.050]a
Understanding  the  illness  2  [13,27]  (+)  0.21  2 1.84  (df  1),
P  =  0.175;
I2 45.60%  [95%  CI
NA]
(+)  0.189
[0.103—0.274]a
Age  3  [13,26,27]  (+)  0.094  2 16.55  (df  2),
P  <  0.001;
I2 87.90%  [95%  CI
66.15—95.68]
(+)  0.070
[0.040—0.171]b
Sex  3  [13,26,27]  (+/—)  0.051  2 16.98  (df  2),
P  <  0.001;
I2 88.20%  [95%  CI
67.22—95.77]
(+/—)  0.041
[0.001—0.110]b
Regularity  of  prescribed  dose  2  [15,26]  (+)  0.40  2 31.79  (df  1),
P  <  0.001;
I2 96.90%  [95%  CI
91.68—98.81]
(+)  0.399
[0.013—0.786]b
Number  of  drugs 4  [13,15,26,27]  (—)  0.14  2 25.98  (df  3),
P  <  0.001;
I2 88.50%  [95%  CI
72.96—95.07]
(—)  0.060
[0.035—0.240]b
Diuretics 2  [27,29] (NS) 0.76  2 7.98  (df  1),
P  =  0.005;
I2 87.50%  [95%  CI
51.21—96.78]
(NS)  0.760
[0.660—0.860]b
Organic  nitrates  1  [13]  (NS)  0.18  NA  NA
Calcium  channel  blockers  1  [13]  (NS)  0.18  NA  NA
Antiarrhythmic  agents  1  [13]  (NS)  0.18  NA  NA
Co-morbidities  1  [27]  (NS)  0.26  NA  NA
CABG  (%)  1  [27]  (NS)  0.49  NA  NA
ICD  (%)  1  [27]  (NS)  0.67  NA  NA
Consultation  duration  1  [13]  (+)  0.23  NA  NA
Consultation  visits  1  [13]  (+)  0.39  NA  NA
Surgical  treatment  1  [13]  (—)  0.18  NA  NA
Prior  hospitalization  for  CHF  1  [27]  (NS)  0.26  NA  NA
Quality  of  life  1  [27]  (NS)  0.14  NA  NA
Depression  1  [27]  (NS)  0.09  NA  NA
Self-management  medication  1  [27]  (NS)  0.11  NA  NA
Pill  box  1  [27]  (NS)  0.43  NA  NA
Married  1  [27]  (NS)  0.26  NA  NA
Education  1  [27]  (NS)  0.04  NA  NA
CABG: coronary artery bypass grafting; CHF: congestive heart failure; CI: conﬁdence interval; df: degrees of freedom; ICD: implantable
cardioverter-deﬁbrillator; NA: not applicable; NS: not stated; SDC: serum digoxin concentration.
Pill count including Medication Event Monitoring System (MEMS).
a Mean effect size [95% CI].
b Median effect size [interquartile range].
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(education  and  counselling  during  hospitalization  or  at  home
with  telephone  follow-ups;  patient  education  by  the  phar-
macist;  mailing  educational  materials;  or  daily  phone  or
video  contact  with  patients)  were  identiﬁed  as  effective  for
improving  compliance  with  HF  medication,  as  suggested  in
previous  studies  [32—35]. These  ﬁndings  agree  with  recent
recommendations  proposed  by  a  French  Task  Force  under
the  auspices  of  the  French  Society  of  Cardiology  [36]. Safe
and  effective  digoxin  immunoassays  may  be  made  available
for  outpatients  to  monitor  their  own  SDC  [37,38].  This  could
empower  some  patients  to  take  care  of  their  own  well-
being  and  may  reduce  the  clinician’s  workload.  However,  the
cost-effectiveness  for  the  test  kit  should  be  assessed  before
implementation.  In  addition,  there  is  a  need  for  ‘imple-
mentation’  research  in  order  to  utilize  such  an  intervention
successfully  in  the  HF  population  [3].
The  ﬁndings  from  this  review  regarding  the  potential
factors  affecting  non-compliance  with  digoxin  could  be  use-
ful  for  detecting  patients  at  risk.  Healthcare  professionals
should  be  aware  of  these  factors,  especially  modiﬁable
ones  with  strong  associations  between  non-compliance  with
digoxin  (e.g.  concomitant  use  of  diuretics,  number  of  ofﬁce
visits  or  pill  box).  However,  the  ﬁndings  must  be  interpreted
with  caution  because  the  number  of  studies  that  reported
such  factors  was  limited  and  they  were  derived  from  uni-
variate  analyses,  which  may  not  fully  reﬂect  the  complexity
of  non-compliance  in  the  real  world.  More  research  on
this  topic  needs  to  be  undertaken  before  the  associa-
tions  between  these  potential  factors  and  non-adherence
to  digoxin  are  more  clearly  understood.
This  review  is  the  ﬁrst  systematic  review  and  meta-
analysis  of  prospective  observational  studies  to  examine
non-compliance  with  digoxin  in  real-life  conditions,  extend-
ing  the  evidence  of  the  long-history  yet  contemporary
medicine  in  terms  of  the  prevalence  rate  of  non-compliance,
the  variations  in  the  prevalence  rates  according  to  clinical
settings,  types  of  non-compliance  and  methods  for  detec-
ting  non-compliance  and  the  potential  factors  affecting
non-compliance  with  digoxin.  Well-accepted  bibliographic
databases  were  used  to  identify  the  included  studies  and
our  review  adheres  to  standard  guidelines  for  meta-analysis
of  observational  studies  in  epidemiology  [39]. This  review
explains  many  of  the  possible  reasons  for  variations  in
non-compliance  prevalence  rates,  which  stemmed  from
differences  in  clinical  settings,  types  of  non-compliance
and  methods  for  detecting  non-compliance.  The  interview
method  yielded  higher  prevalence  rates  of  non-compliance
compared  with  the  SDC  method.  This  may  be  because  an
interview,  especially  face-to-face,  may  encourage  patients
to  report  their  use  of  medication.  However,  this  method
can  be  susceptible  to  misrepresentation  and  tends  to  result
in  health-care  providers  overestimating  patient  adherence
[40].  SDC  measurement  is  considered  an  objective  method
but  it  does  not  always  reﬂect  patient  behaviour  towards
medication  and  may  be  unreliable  where  additional  patholo-
gies  are  present  (e.g.  impaired  renal  excretion  or  electrolyte
disturbance)  [41]. Furthermore,  SDC  cut-off  points  vary
according  to  the  indication.  For  example,  an  SDC  of
0.5—0.9  ng/mL  is  suggested  for  patients  with  HF  [8]  but  suit-
able  SDCs  for  patients  with  accompanying  conditions  are
lacking.  Although,  there  is  no  ‘gold  standard’  for  detec-
ting  non-compliance,  combining  different  methods  (e.g.  theation  515
ombined  method  of  interview  conﬁrmed  by  SDC)  to  assess
on-compliance  may  signiﬁcantly  increase  the  quality  of  the
ata  in  this  regard  [41,42].
Despite  our  efforts  to  explain  the  heterogeneity,  vari-
tions  remain  for  the  studies  that  reported  overdosing  of
igoxin  employing  the  SDC  method.  This  may  be  explained
y  differences  in  the  SDC  cut-off  points  for  non-compliance.
lthough  this  review  might  have  missed  some  studies  that
et  the  inclusion  criteria  by  restricting  the  search  to  English
ublications  only,  hand  searching  of  the  reference  lists  was
sed  as  a  supplementary  method  to  maximize  the  number
f  identiﬁed  publications.  While  Cochrane’s  risk  of  bias  was
dopted  to  assess  the  quality  of  the  studies,  such  criteria
re  more  suitable  for  assessing  the  methodological  quality  of
andomized  studies  [43]; this  precludes  such  an  assessment
n  our  review.
onclusions
n  summary,  non-compliance  is  prevalent  among  patients
ith  HF  and/or  AF  treated  with  digoxin.  The  effectiveness
f  digoxin  in  contemporary  treatment  of  HF  and/or  AF  would
e  improved  if  the  risk  of  non-compliance  with  digoxin  could
e  minimized  to  a  level  that  causes  no  harm  to  patients  and
chieves  the  therapeutic  effect.
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